Patents by Inventor Jeffrey Barrick

Jeffrey Barrick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230026506
    Abstract: Provided herein are genetically engineered bacteria that are native to a host insect microbiome. Further provided are methods of inducing RNA interference in an insect, such as a bee, by administering the genetically engineered bacteria.
    Type: Application
    Filed: May 19, 2022
    Publication date: January 26, 2023
    Inventors: Nancy Moran, Jeffrey Barrick, Sean Leonard
  • Patent number: 11382989
    Abstract: Provided herein are genetically engineered bacteria that are native to a host insect microbiome. Further provided are methods of inducing RNA interference in an insect, such as a bee, by administering the genetically engineered bacteria.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: July 12, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Nancy Moran, Jeffrey Barrick, Sean Leonard
  • Publication number: 20190015528
    Abstract: Provided herein are genetically engineered bacteria that are native to a host insect microbiome. Further provided are methods of inducing RNA interference in an insect, such as a bee, by administering the genetically engineered bacteria.
    Type: Application
    Filed: July 9, 2018
    Publication date: January 17, 2019
    Inventors: Nancy Moran, Jeffrey Barrick, Sean Leonard
  • Publication number: 20130029342
    Abstract: Riboswitches are structural elements in mRNA that change state when bound by a trigger molecule, and are thus able to regulate gene expression. They can be dissected into two separate domains: one that selectively binds the target (aptamer domain) and another that influences genetic control (expression platform domain). Bacterial glycine riboswitches consist of two tandem aptamer domains which cooperatively bind glycine to regulate the expression of downstream genes. These natural switches are targets for antibiotics and other small molecule therapies. Modified versions of these natural riboswitches can be employed as designer genetic switches that are controlled by specific effector compounds. Disclosed are isolated and recombinant riboswitches, and compositions and methods for selecting and identifying compounds that can activate, inactivate, or block a riboswitch.
    Type: Application
    Filed: July 31, 2012
    Publication date: January 31, 2013
    Inventors: Ronald R. Breaker, Jeffrey Barrick, Maumita Mandal
  • Publication number: 20090117545
    Abstract: It has been discovered that certain natural mRNAs serve as metabolite-sensitive genetic switches wherein the RNA directly binds a small organic molecule. This binding process changes the conformation of the mRNA, which causes a change in gene expression by a variety of different mechanisms. Modified versions of these natural “riboswitches” (created by using various nucleic acid engineering strategies) can be employed as designer genetic switches that are controlled by specific effector compounds. Such effector compounds that activate a riboswitch are referred to herein as trigger molecules. The natural switches are targets for antibiotics and other small molecule therapies.
    Type: Application
    Filed: October 7, 2005
    Publication date: May 7, 2009
    Inventors: Ronald R. Breaker, Jeffrey Barrick, Maumita Mandal
  • Publication number: 20050053951
    Abstract: It has been discovered that certain natural mRNAs serve as metabolite-sensitive genetic switches wherein the RNA directly binds a small organic molecule. This binding process changes the conformation of the mRNA, which causes a change in gene expression by a variety of different mechanisms. Modified versions of these natural “riboswitches” (created by using various nucleic acid engineering strategies) can be employed as designer genetic switches that are controlled by specific effector compounds. Such effector compounds that activate a riboswitch are referred to herein as trigger molecules. The natural switches are targets for antibiotics and other small molecule therapies.
    Type: Application
    Filed: September 22, 2003
    Publication date: March 10, 2005
    Inventors: Ronald Breaker, Ali Nahvi, Narasimhan Sudarsan, Margaret Ebert, Wade Winkler, Jeffrey Barrick, John Wickiser